The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Advances in targeting cyclic nucleotide phosphodiesterases
Open accessAbstract
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides, their signalling pathways and, consequently, myriad biological responses in health and disease. Currently, a small number of PDE inhibitors are used clinically for treating the pathophysiological dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease. However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Baillie, G. S., Sood, A., McPhee, I., Gall, I., Perry, S. J., Lefkowitz, R. J., & Houslay, M. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262787199 · Cited by 360
RetractedInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Cardiac excitation–contraction coupling
Bers, D. M. (2002) · Nature · doi:10.1038/415198a · Cited by 4,744
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Self-citation
Cited by
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
“Receptors for activated C kinase 1 (RACK1) and Akinase-anchoring proteins (AKAPs) and proteins that contain SH3 domains act as the interacting proteins that affect the intracellular localization and function of PDE4 (Maurice et al., 2014).”
BackgroundHydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs
Li, L., Yin, Q., Kuss, P., Maliga, Z., Millán, J. L., Wu, H., & Mitchison, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1661 · Cited by 533
Transcriptional Architecture of Synaptic Communication Delineates GABAergic Neuron Identity
Paul, A., Crow, M., Raudales, R., He, M., Gillis, J., & Huang, Z. J. (2017) · Cell · doi:10.1016/j.cell.2017.08.032 · Cited by 421
Molecular Physiology of Membrane Guanylyl Cyclase Receptors
Kuhn, M. (2016) · Physiological Reviews · doi:10.1152/physrev.00022.2015 · Cited by 356
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., et al. (2015) · Nature · doi:10.1038/nature14332 · Cited by 353
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
Raker, V. K., Becker, C., & Steinbrink, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00123 · Cited by 319
Current evidence on the effect of dietary polyphenols intake on chronic diseases
Costa, C., Tsatsakis, A., Mamoulakis, C., Teodoro, M., Briguglio, G., Caruso, E., Tsoukalas, D., Margina, D., Dardiotis, E., Kouretas, D., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.10.023 · Cited by 258
Alvarez, M. M., Liu, J. C., Trujillo-de Santiago, G., Cha, B.-H., Vishwakarma, A., Ghaemmaghami, A. M., & Khademhosseini, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.026 · Cited by 256
Lokireddy, S., Kukushkin, N. V., & Goldberg, A. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522332112 · Cited by 228
Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838449 · Cited by 137
cAMP: From Long-Range Second Messenger to Nanodomain Signalling
Musheshe, N., Schmidt, M., & Zaccolo, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.006 · Cited by 132
Interaction between integrin α5 and PDE4D regulates endothelial inflammatory signalling
Yun, S., Budatha, M., Dahlman, J. E., Coon, B. G., Cameron, R. T., Langer, R., Anderson, D. G., Baillie, G., & Schwartz, M. A. (2016) · Nature Cell Biology · doi:10.1038/ncb3405 · Cited by 96
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
Garvie, C. W., Wu, X., Papanastasiou, M., Lee, S., Fuller, J., Schnitzler, G. R., Horner, S. W., Baker, A., Zhang, T., Mullahoo, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24495-w · Cited by 85
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0206-2022 · Cited by 85
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P., & Shi, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01043-6 · Cited by 67
Liang, G., Kow, A. S. F., Yusof, R., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2024) · Biomedicines · doi:10.3390/biomedicines12010184 · Cited by 68
SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP
Shimizu-Albergine, M., Van Yserloo, B., Golkowski, M. G., Ong, S.-E., Beavo, J. A., & Bornfeldt, K. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611424113 · Cited by 45
Schmidt, M., Cattani-Cavalieri, I., Nuñez, F. J., & Ostrom, R. S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.05.002 · Cited by 30
Metadata
- Authors
- Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-04
- Volume
- 13
- Issue
- 4
- Pages
- 290-314
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972029787
- Cited by
- 776
- References
- 222
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.